MosheYairLevyMD

Hematology • Dallas, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Levy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Levy's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1065

Fax+1 214-370-1190

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
UPMC Medical EducationResidency, Internal Medicine, 1999 - 2002
University of Wisconsin School of Medicine & Public HealthClass of 1999

Certifications & Licensure

TX State Medical License 2008 - 2025
MD State Medical License 2002 - 2010
PA State Medical License 2000 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
Completed
Phase 1
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS Start of enrollment: 2020 Dec 04
Recruiting
Phase 1, Phase 2
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS Start of enrollment: 2022 Mar 17
Active, not recruiting
Phase 2
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) Start of enrollment: 2021 Apr 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.
Ehab L Atallah, Michael J Mauro, Koji Sasaki, Moshe Y Levy, Paul Koller
Future Oncology. 2024-01-01
36 citations
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria
Nature Medicine. 2023-10-01

Lectures

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-cell Lymphoma and Other NON-Hodgkin’s B-cell Lymphomas – a Phase 2 StudyDecember 2021

Press Mentions

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial ResultsAugust 13th, 2020